CO63 Comparative Clinical Effectiveness of Monoclonal Antibodies for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-Analysis

To evaluate the relative clinical effectiveness of five monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, rituximab, ublituximab) as first-line disease-modifying therapies (DMT) for relapsing forms of multiple sclerosis (MS); and to compare these treatments to placebo and oral DMTs (dimethyl fumarate, fingolimod, ozanimod, ponesimod, and teriflunomide).

Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: D. Nikitin, G. Lin, A. McKenna, S. Herron-Smith, J. Campbell, F.O. Agboola Source Type: research